|
| 10. |
STOCK-BASED
COMPENSATION |
Historically,
stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, with expiration
10 years from the date they are granted, and generally vest over a one to three-year period for employees and members of the Board. Upon
exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to
Board members and employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under
certain circumstances.
The
following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during
the three-month periods ended March 31, 2022 and 2021.
SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS
| |
|
March
31, 2022 |
|
|
March
31, 2021 |
|
| |
|
|
(unaudited) |
|
| Risk-free
interest rate |
|
|
1.76 |
% |
|
|
0.78 |
% |
| Expected
life |
|
|
6.0
years |
|
|
|
6.0
years |
|
| Expected
volatility |
|
|
129.93 |
% |
|
|
134.79 |
% |
| Dividend
yield |
|
|
- |
|
|
|
- |
|
During
March 2021, the Company granted 312,500 stock options with an exercise price of $6.00 and 152,500 RSUs. The market value of the Company’s
common stock was $5.00 at the grant date of these awards. The Company recognized approximately $0.3 million and $0.3 million of stock-based
compensation expense during the three-month periods ended March 31, 2022 and 2021, respectively. The following table has a breakout of
stock-based compensation expense by line item.
SCHEDULE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD
| |
|
Three
Months Ended |
|
| |
|
March
31, |
|
| |
|
2022 |
|
|
2021 |
|
| |
|
|
(unaudited) |
| Cost
of revenue |
|
$ |
27 |
|
|
$ |
48 |
|
| Sales
and marketing |
|
|
44 |
|
|
|
47 |
|
| Research
and development |
|
|
- |
|
|
|
35 |
|
| General
and administrative* |
|
|
254 |
|
|
|
156 |
|
| Total
stock compensation expense |
|
$ |
325 |
|
|
$ |
286 |
|
|